Ketamine Johnson & Johnson

Ketamine Nasal Spray Approved

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Gizmodo · 21h

Ketamine Nasal Spray Approved as Standalone Treatment for Tough Depression Cases

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a standalone therapy for cases of depression that haven’t responded to other options.

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

Inquirer on MSN3d

Controlled drug Ketamine a lifeline for patients with severe depression in S’pore

Ketamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.

Evening Standard on MSN14d

Government will do ‘whatever it takes’ to clamp down on ketamine use

In the year ending March 2023, an estimated 299,000 people aged 16 to 59 had reported ketamine use (Alamy/PA) Policing minister Dame Diana Johnson will write to the Advisory Council on the Misuse ...

US FDA approves standalone use of J&J’s ketamine-derived depression treatment

The US Food and Drug Administration (FDA) has expanded the approval for Johnson & Johnson’s nasal spray Spravato to allow its standalone use in patients with depression, the company said on Jan 21.

Trump pulls back Biden drug pricing action

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results